Mutational alterations of the p16CDKN2A tumor suppressor gene have low incidence in mesenchymal chondrosarcoma

Oncology Research

Volumn 12, Issue 1, 2000, Pages 5-10

  Bae, Dae Kyung ^a   Park, Yong Koo ^a,c   Chi, Sung Gil ^a   Lee, Chun Woo ^a   Unni, K Krishnan ^b  

^a Kyung Hee University Hospital   (South Korea)

^b MAYO CLINIC   (United States)

^c Kyung Hee University College of Medicine   (South Korea)

Author keywords

Mesenchymal chondrosarcoma; p16CDKN2A tumor suppressor gene

Indexed keywords

PRIMER DNA; PROTEIN P16INK4A;

ARTICLE; BONE TUMOR; CHEMISTRY; CHONDROSARCOMA; GENETICS; HUMAN; LEG; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BONE NEOPLASMS; CHONDROSARCOMA, MESENCHYMAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENES, P16; HUMANS; LEG; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL;

EID: 0034575947     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000001108747381     Document Type: Article

References (44)

1. 1 cyclins. Cell 73:1059-1065; 1993.
2. Pines, J. Cyclins and cyclin-dependent kinases: Take your partners. Trends Biochem. Sci. 18:195-197; 1993.
3. Hengst, L.; Reed, S. I. Inhibitors of the Cip/Kip family. Curr. Topic Microbiol. Immunol. 227:25-41; 1998.
4. 1 cyclin-dependent kinases. Genes Dev. 9:1149-1163; 1995.
5. King, R. W.; Deshaies, R. J.; Peters, J. M.; Kirschner, M. W. How proteolysis drives the cell cycle. Science 274:1652-1659; 1996.
6. Serrano, M.; Hannon, G. J.; Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707; 1993.
7. Kamb, A.; Gruis, N. A.; Weaver-Feldhaus, J.; Liu, Q.; Harshman, K.; Tavtigian, S. V.; Stocken, E.; Day, R. W.; Johnson, B. E.; Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440; 1994.
8. Hannon, G. J.; Beach, D. p15 INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261; 1994.
9. Hussussian, C. J.; Struewsing, J. P.; Goldstein, A. M.; Higgins, P. A. T.; Ally, D. S.; Sheehan, M. D.; Clark, W. H., Jr.; Tucker, M. A.; Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet. 8:15-21; 1994.
10. Kamb, A.; Shattuck-Eidens, D.; Eeles, R.; Liu, Q.; Gruis, N. A.; Ding, W.; Hussey, C.; Tran, T.; Miki, Y.; Wasver-Feldhaus, J.; McClure, M.; Aitken, J. F.; Anderson, D. E.; Bergman, W.; Frants, R.; Goldbar, D. E.; Green, A.; MacLennan, R.; Martin, N. G.; Meyer, L. J.; Youl, P.; Zone, J. J.; Skolnick, M. H.; Cannon-Albright, L. A. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8:23-26; 1994.
11. Goldstein, A. M.; Fraserr, M. C.; Struewing, J. P.; Hussussian, C. J.; Ranade, K.; Zametkin, D. P.; Fontaine, L. S.; Organic, S. M.; Dracopoli, N. C.; Clark, W. H., Jr. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med. 333:970-974; 1995.
12. Holland, E. A.; Beaton, S. C; Becker, T. M.; Grulet, O. M.; Peters, B. A.; Rizos, H.; Kefford, R. F.; Mann, G. J. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 11:2289-2294; 1995.
13. Chi, S.-G.; deVere White, R. W.; Muenzer, J. T.; Gumerlock, P. H. Frequent alterations of CDKN2 (p16 INK4A/MTS1) expression in human primary prostate carcinomas. Clin. Cancer Res. 3: 1889-1897; 1997.
14. Lee, M. H.; Reynisdottir, I.; Massague, J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9:639-649; 1995.
15. Matsuoka. S.; Edwards, M. C.; Bai, C.; Parker, S.; Zhang, P.; Baldini, A.; Harper, J. W.; Elledge, S. J. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9:650-662; 1995.
16. Zhang, P.; Liegeois, N. J.; Wong, C.; Finegold, M.; How, H.; Thompson, J. C.; Silverman, A.; Harper, J. W.; DePinho, R. A.; Elledge, S. J. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387:151-158; 1997.
17. Yan, Y.; Frisen, J.; Lee, M. H.; Massague, J.; Barbacid, M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 11:973-983; 1997.
18. Zhang, P.; Wong, C; Liu, D.; Finegold, M.; Harper, J. W.; Elledge, S. J. P21(CIP1) and p57 (KIP2) control muscle differentiation at the myogenin step. Genes Dev. 13:213-224; 1999.
19. Nakashima, Y.; Unni, K. K.; Shives, T. C; Swee, R. G.; Dahlin, D. C. Mesenchymal chondrosarcoma of bone and soft tissue. Cancer 57:2444-2453; 1986.
20. Cairns, P.; Mao, L.; Merlo, A.; Lee, D. J.; Schwab, D.; Eby, Y.; Tokino, K.; van der Riet, P.; Blaugrund, J. E.; Sidransky, D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-417; 1994.
21. Ohta, M.; Nagai, H.; Shimizu, M.; Rasio, D.; Berd, D.; Mastrangelo, M.; Singh, A. D.; Shields, J. A.; Shields, C. L.; Croce, C. M.; Huebner. K. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene CDK4I, in melanoma. Cancer Res. 54:5269-5272; 1994.
22. Spruck, C. H., III; Gonzalea-Zulueta, M.; Shibata, A.; Simoneau, A. R.; Lin, M. F.; Gonzales, F.; Tsai, Y. C.; Jones, P. A. p16 gene in uncultured tumours. Nature 370:183-184; 1994.
23. Xu, L.; Sgroi, D.; Sterner, C. J.; Beauchamp, R. L.; Pinney, D. M.; Keel, S.; Ueki, K.; Rutter, J. L.; Buckler, A. J.; Louis, D. N.; Gusella, J. F.; Ramesh, V. Mutational analysis of CDKN2 (MTS1/ p16 ink4) in human breast carcinomas. Cancer Res. 54:5262-5264; 1994.
24. Park. Y.-K.; Chi, S. G.; Kim, Y. W.; Park, H. R.; Unni, K. K. Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma. Oncol. Rep. 6:1261-1266; 1999.
25. Chi, S.-G.; deVere White, R. W.; Meyers, F. J.; Siders, D.; Lee, F.; Gumerlock, P. H. p53 in prostate: Frequent expressed transition mutations. J. Natl. Cancer Inst. 86:926-933; 1994.
26. Caldas, C.; Hahn, S. A.; da Costa, L. T.; Redston, M. S.; Schutte, M.; Seymour, A. B.; Weinstein, C. L.; Hruban, R. H.; Yeo, C. J.; Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8:27-32; 1994.
27. Chen, J.-Q.; Jhanwar, S. C.; Klein, W. M.; Bell, D. W.; Lee, W.-C.; Altomare, D. A.; Nobori, T.; Olopade, O. L; Buckler, A. J.; Testa, J. R. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54:5547-5551; 1994.
28. Hayashi, N.; Sugimoto, Y.; Tsuchiya, E.; Ogawa, M.; Nakamura, Y. Somatic mutations of the MTS (multiple tumor suppressor) 1/ CDK41 (cyclin dependent kinase 4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Commun. 202:1426-1430; 1994.
29. Mori, T.; Miura, K.; Aoki, T.; Nishihar, T.; Mon, S.; Nakamura, Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 54:3396-3397; 1994.
30. Ogawa, S.; Hirano, N.; Sato, N.; Takahashi, T.; Hangaishi, A.; Tanaka, K.; Kurosawa, M.; Tanaka, T.; Mitani, K.; Yazaki, Y.; Kirai, H. Homozygous loss of the cyclin-dependent kinase 4-in-hibitor (p16) gene in human leukemia. Blood 84:2431-2435; 1994.
31. Patino-Garcia, A.; Sierrasesumaga, L. Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genet. Cytogenet. 98:50-55; 1997.
32. Wei, G.; Lonardo, F.; Ueda, T.; Kim, T.; Huvos, A. G.; Healey, J. H.; Lodanyi, M. CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int. J. Cancer 80:199-204; 1999.
33. Serena Benassi, M.; Molendini, L.; Bamberi, G.; Ragazzini, P.; Rosa Sollazzo, M.; Merli, M.; Asp, J.; Magagnoli, G.; Balladelli, A.; Bertoni, F.; Picci, P. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int. J. Cancer 84:489-493; 1999.
34. Dowdy, S. F.; Hinds, P. W.; Louie, K.; Reed, S. I.; Arnold, A.; Weinberg, R. A. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 73:499-511; 1993.
35. Ewen, M. E.; Sluss, H. K.; Sherr, C. J.; Matsushime, H.; Kato, J.; Livingston, D. M. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497; 1993.
36. Kato, J.; Matsushime, H.; Hiebert, S. W.; Ewen, M. E.; Sherr, C. J. Direct binding of cyclin D to the retinoblastoma gene product 9pRb and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7:331-342; 1993.
37. Muller, H.; Lukas, J.; Schneider, A.; Warthoe, P.; Bartek, J.; Eilers, M.; Strauss, M. Cyclin D1 expression is regulated by the retinoblastoma protein. Proc. Natl. Acad. Sci. USA 91:2945-2949; 1994.
38. Li, Y.; Nichols, M. A.; Shay, J. W.; Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 54:6078-6082; 1994.
39. Okamoto, A.; Demetrick, D. J.; Spillare, E. A.; Hagiwara, K.; Hussain, S. P.; Bennett, W. P.; Forrrester, K.; Gerwin, B.; Serrano, M.; Beach, D. H.; Harris, C. C. Mutations and altered expression of p16INK4Q in human cancer. Proc. Natl. Acad. Sci. USA 91: 11044-11049; 1994.
40. Jagasia, A. A.; Block, J. A.; Diaz, M. O.; Nobori, T.; Gitelis, S.; Inerot, S. E.; Iyer, A. P. Partial deletions of the CDKN2 and MTS2 putative tumor suppressor genes in a myxoid chondrosarcoma. Cancer Lett. 105:77-90; 1996.
41. Jagasia, A. A.; Block, J. A.; Qureshi, A.; Diaz, M. O.; Nobori, T.; Gitelis, S.; Iyer, A. P. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett. 105:91-103; 1996.
42. Bovee, J. V. M. G.; Cleton-Jansen, A.; Kuipers-Dijkshoorn, N. J.; van den Brock, L. M. C. M.; Taminiau, A. H. M.; Cornelisse, C. J.; Hogendoorn, P. C. W. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Genes Chromosomes Cancer 26: 237-246; 1999.
43. Herman, J.; Jen, J.; Merlo, A.; Baylin, S. Hypermethylation-associated inactivation indicates a tumor suppressor role for p151NK4B1. Cancer Res. 56::722-727; 1996.
44. Otterson, G.; Khleif, S.; Chen, W.; Coxon, A. B.; Kaye, F. J. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza-2′ deoxycystidine. Oncogene 11:1211-1216; 1995.